Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a **combination of three agents**: **felypressin**, **lidocaine**, and **prilocaine**. - **Felypressin** is a synthetic non-catecholamine vasoconstrictor structurally related to vasopressin, used in dentistry to limit blood flow and prolong the effect of local anesthetics[2][5]. - **Lidocaine** is an amide-type local anesthetic that stabilizes neuronal membranes by inhibiting the ionic fluxes required for the initiation and conduction of nerve impulses, causing a reversible local loss of sensation[4]. - **Prilocaine** is an amide local anesthetic similar to lidocaine but with less vasodilatory activity, sometimes combined with vasoconstrictors for dental anesthesia[5]. This combination could theoretically offer local anesthesia with vasoconstriction, which may be preferred in patients where adrenaline-containing preparations are contraindicated. **Felypressin** in the combination serves as the vasoconstrictor in place of epinephrine, aiming to reduce cardiovascular side effects, particularly in cardiac patients[1][5]. However, this exact three-agent combination (felypressin + lidocaine + prilocaine) does not correspond to any well-known, widely marketed commercial formulation; combinations of prilocaine + felypressin and lidocaine + epinephrine are common, and felypressin is sometimes combined with a single anesthetic in dental solutions[2][5]. No commercial product, clinical trial, or regulatory label specifically documents the standardized combination of all three (felypressin + lidocaine + prilocaine) as a single preparation for medical or dental use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on felypressin + lidocaine + prilocaine.